help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0440
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/10/4175    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dardano, A.
Right arrow Articles by Monzani, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dardano, A.
Right arrow Articles by Monzani, F.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Thyroid
Right arrow Cardiovascular Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 10 4175-4178
Copyright © 2006 by The Endocrine Society


BRIEF REPORT

Recombinant Human Thyrotropin Reduces Endothelium-Dependent Vasodilation in Patients Monitored for Differentiated Thyroid Carcinoma

Angela Dardano, Lorenzo Ghiadoni, Yvonne Plantinga, Nadia Caraccio, Alessia Bemi, Emiliano Duranti, Stefano Taddei, Ele Ferrannini, Antonio Salvetti and Fabio Monzani

Department of Internal Medicine, University of Pisa, 56126 Pisa, Italy

Address all correspondence and requests for reprints to: Fabio Monzani, M.D., Department of Internal Medicine, University of Pisa, via Roma 67, 56126 Pisa, Italy. E-mail: fmonzani{at}med.unipi.it.

Aim: We evaluated endothelial-dependent vasodilation after administration of recombinant human TSH (rhTSH) in patients monitored for differentiated thyroid carcinoma. The role of inflammation and oxidative stress was also assessed.

Protocol: Twenty-four patients (21 women, mean age 40.5 ± 9.2 yr) received rhTSH (0.9 mg daily) on 2 consecutive days. At baseline and the day after the second rhTSH injection, endothelium-dependent vasodilation as flow-mediated dilation (FMD, induced by 5 min of forearm ischemia) and endothelium-independent vasodilation (glyceril trinitrate 25 µg, sublingual) were evaluated by high-resolution ultrasound in the brachial artery. At each experimental time, blood was drawn for the evaluation of thyroglobulin, TSH, free T3, free T4, as well as IL-6, C reactive protein, TNF{alpha}, lipoperoxides, and ferric reducing antioxidant power levels as markers of inflammation and oxidative stress.

Results: At baseline, patients’ serum TSH values were below the normal range [0.12 mIU/liter (range 0.01–0.30)] in the face of normal free T4 and free T3 levels; FMD (8.9 ± 3.4 vs. 9.2 ± 3.1%, respectively) and response to glyceril trinitrate (11.0 ± 4.3 vs. 10.8 ± 4.7%, respectively) were similar in patients and controls. All the patients had serum thyroglobulin value less than 1 ng/ml, suggesting the absence of cancer recurrences. Besides the expected elevation of serum TSH, rhTSH induced a significant impairment of FMD (7.4 ± 3.0 vs. 8.9 ± 3.4%; P < 0.01) along with a significant elevation of blood IL-6 (P = 0.01), TNF{alpha} (P < 0.001), and lipoperoxide levels (P = 0.01), as well as a reduction of ferric reducing antioxidant power (P = 0.01).

Conclusions: rhTSH administration acutely impaired endothelium-dependent vasodilation, possibly through the induction of low-grade inflammation and reduced nitric oxide availability by oxidative stress.




This article has been cited by other articles:


Home page
EndocrinologyHome page
T. T. Antunes, A. Gagnon, M. L. Langille, and A. Sorisky
Thyroid-Stimulating Hormone Induces Interleukin-6 Release from Human Adipocytes through Activation of the Nuclear Factor-{kappa}B Pathway
Endocrinology, June 1, 2008; 149(6): 3062 - 3066.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Napoli, B. Biondi, V. Guardasole, C. D'Anna, A. De Sena, C. Pirozzi, D. Terracciano, C. Mazzarella, M. Matarazzo, and L. Sacca
Enhancement of Vascular Endothelial Function by Recombinant Human Thyrotropin
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1959 - 1963.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
B. O. Asvold, T. Bjoro, T. I. L. Nilsen, D. Gunnell, and L. J. Vatten
Thyrotropin Levels and Risk of Fatal Coronary Heart Disease: The HUNT Study
Arch Intern Med, April 28, 2008; 168(8): 855 - 860.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A. Dardano and F. Monzani
Recombinant human TSH acutely impairs endothelium-dependent vasodilation
Eur. J. Endocrinol., September 1, 2007; 157(3): 367 - 367.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society